Here’s what we’re watching in chemistry business news this week Since the start of the year, five biotech companies have held IPOs: radiopharmaceutical maker Aktis Oncology; alopecia drug developer Veradermics; cancer and neuroscience firm—and 2021 C&EN Start-up to Watch—Eikon Therapeutics; eye disease–focused SpyGlass Pharma; and small-molecule and antibody developer Agomab Therapeutics. The exception was Eikon, which was down less than 20%. Aktis’s IPO “was just an incredible success,” says Christiana Bardon, managing partner of MPM BioImpact, which invested in the firm, noting “Since then, there’s just been a lot of enthusiasm.” Several other biotechs are beginning to eye the possibility of going public this year, including Parabilis Medicines, previously known as FogPharma; precision-medicine start-up Mirador Therapeutics; and antifungal-developer F2G. Feb. 10 Business Watch: Biotech IPOs are back; FMC may soon be for sale The firm’s scientists can then plumb these repertoires for the best antibodies to treat viral infections and cancer. Under this partnership, Memo will use Dropzylla to develop recombinant polyclonal IgG (immunoglobulin G) antibodies that CSL may exclusively license.

Original title: “Feb. 10 Business Watch: Biotech IPOs are back; FMC may soon be for sale”

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical testing, is focused on B cell–driven autoimmune diseases.

Original title: “Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune”

Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” in damages, John Kuckelman, the pharma’s general counsel, said. The wellness platform pulled its version of the drug just days after launching it.

Original title: “Novo Sues Hims & Hers Over Compounded Version of Oral Wegovy Pill”

With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.

Original title: “Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment”

Generate Biomedicines’ IPO aims to fund Phase 3 GB-0895 for severe asthma/COPD and expand its pipeline. Learn more about GENB stock here. Generate Biomedicines is pursuing an IPO to fund its clinical trials and pipeline expansion efforts. IPOs.He also leads the investing group IPO Edge, which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates. The IPO will likely be in significant demand from institutional investors. Looking for more investing ideas like this one? Get them exclusively at IPO Edge.

Original title: “Generate Biomedicines Begins IPO Push With Major Collaboration Deals (GENB) | Seeking Alpha”

US IPOs today: Once Upon a Farm, AgomAb and SpyGlass line up as fresh listings test demand - TechStock² The company intends to use the funds to repay debt, purchase equipment, and support other corporate expenses. Goldman Sachs and J.P. Morgan are steering the transaction. 3 · Belgian biotech AgomAb Therapeutics, which specializes in immunology and inflammatory diseases, set its IPO price at $16 per American depositary share — those U.S.-listed certificates that stand for foreign company stock. Cambridge Acquisition’s units hovered at $9.98, with SPACSphere’s units just above at $10.04. 7 · The week kicked off with a mixed bag of debuts. Electrical equipment maker Forgent Power Solutions, which pulled in $1.51 billion in its IPO, gained roughly 8.4% to $31.44. Furniture retailer Bob’s Discount Furniture climbed 5.6% to $17.98, while biotech firm Eikon Therapeutics slipped 1.2% to $14.82. Once Upon a Farm, the children’s food brand connected to actress Jennifer Garner, is gearing up for its NYSE debut on Friday. The company priced its U.S. IPO at $18 per share. Friday’s slate may not be a blockbuster, but it offers a clear snapshot of risk appetite — with consumer, biotech, and blank-check stocks all hitting the market. ASX IPO watch: MB Gold pops on debut after selloff as next floats line up View all · Bonduelle Reports January 2026 Share and Voting Rights Totals · February 6, 2026, 1:04 PM EST. Bonduelle, a French partnership limited by shares, disclosed its monthly information on January 31, 2026.

Original title: “US IPOs today: Once Upon a Farm, AgomAb and SpyGlass line up as fresh listings test demand”

Sales of Johnson & Johnson’s esketamine-based nasal spray jumped in the fourth quarter last year, priming the pump for a suite of other pharmas, including AbbVie, champing at the bit with their own psychedelics.

Original title: “AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing”

With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.

Original title: “Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline”

Just three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds with its stock now trading under the ticker AGMB. Just three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds with its stock now trading under the ticker AGMB. ... Agomab is advancing antibody therapies aimed at fibrotic complications, including fibrostenosing Crohn’s disease, with multiple programs now in clinical development. Agomab’s Nasdaq debut comes in the same week as cancer-focused biotech Eikon Therapeutics completed the largest IPO of the year so far, marking an uptick in new biotech listings after a much quieter period. It seems to indicate public investors are once again willing to back biotech stories with defined clinical trajectories. While IPOs are picking up in the U.S., the European public market has been more stagnant in 2026 so far, with no IPO in the U.K. or in Europe. ... AgomAb Therapeutics has filed for an initial public offering (IPO) in the U.S., looking to tap public markets to fund the next stage of development for its pipeline in fibrotic and inflammatory diseases. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔ ... Investors are showing enormous interest in the topic of longevity, as well as in combating chronic diseases. This is because these diseases have a negative impact on life expectancy. The USA and China … more ➔ ... This issue focuses on the art of upscaling industrial biotechnology in Europe, the impact of the Trump factor on the life sciences and the European Commission's new billion-euro fund for emerging … Alongside its lead program in fibrostenosing Crohn’s disease, Agomab’s pipeline includes AGMB-447, a lung-targeted ALK5 inhibitor being developed for idiopathic pulmonary fibrosis (IPF) and other lung fibrosis indications. The company is currently exploring dosage in phase 1. IPF and related lung fibrosis indications have seen other clinical activity this year. For example, Swedish biotech Cereno Scientific recently announced plans to broaden the clinical focus for its HDAC inhibitor to include pulmonary hypertension associated with interstitial lung disease (PH-ILD), a serious complication in ILD patients.

Original title: “Agomab goes public on Nasdaq as biotech IPOs top $1bn in a single week - European Biotechnology Magazine”

Eikon Therapeutics prices $381 IPO as biotech public offerings surge, with analysts predicting 40-60 companies going public in 2026 Eikon's public debut comes during a busy week for biotech IPO activity. Earlier this week, dermatology-focused biotech Veradermics announced the pricing of its upsized initial public offering of 15 million shares of its common stock priced at $17.00 per share. According to Eikon's US Securities and Exchange Commission filing, the company's highest priority for the IPO proceeds will be advancing its four clinical-stage candidates through development. As previously reported by BioXconomy, Eikon has raised over $1.1 billion in private funding since its 2019 founding. “Being optimistic, we may see a return to levels seen pre-pandemic, with 40–60 companies going public on Western exchanges in 2026,” Ben Folwell, senior analyst at Evaluate, told BioXconomy following Aktis Oncology’s IPO listing at the start of the year. ... Investival Showcase USA brings visionary life-science innovators together to secure game-changing capital and partnerships. The offering will generate approximately $381 million and is expected to close on February 6. Eikon also granted underwriters a 30-day option to purchase up to an additional 3.1 million shares at the initial public offering (IPO) price.

Original title: “Eikon Therapeutics prices IPO at $381m”

30, the New York-based biotech had $11.9 million in cash and cash equivalents, according to a November filing with the Securities and Exchange Commission (SEC). <strong>Applied Tx</strong>’s board has unanimously greenlighted the acquisition, which is slated ...

Original title: “Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share”

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers.

Original title: “BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition - MedCity News”

Rare disease drug developers came ... of the year—Amgen’s acquisition of rare disease focused Horizon Therapeutics for <strong>$27.3 billion</strong>....

Original title: “Rare Disease Drug Developers Struggle Through a Difficult Finance Environment in 2022 - Global Genes”

Two significant acquisitions ushered in 2023 for rare disease drug developers with Chiesi Farmaceutici’s acquisition of Amryt Pharma for up to $1.5 billion and Ipsen’s acquisition of Albireo for up to $1.2 billion.

Original title: “Rare Disease Therapeutics M&A off to a Strong Start in 2023, But Financings Remain Lackluster - Global Genes”

... According to a new BioPharma Dive analysis, corporate-related funds such as <strong>Novo Holdings, Eli Lilly and Sanofi Ventures</strong> have been among the most active investors in biotech startups this year.

Original title: “Sanofi drug acquired in buyout succeeds in rare disease trial | BioPharma Dive”

<strong>Aktis has a partnership in place with Eli Lilly</strong> and has received investments from multiple large pharmaceutical companies, among them Merck &amp; Co., Novartis and Bristol Myers Squibb.

Original title: “Radiopharmaceutical specialist Aktis seeks an IPO | BioPharma Dive”

<strong>BioCryst is acquiring Astria Therapeutics</strong> in a cash-and-stock deal that gives the company a long-acting preventive therapy for the rare disease hereditary angioedema. By Ned Pagliarulo, Jacob Bell and Julia Himmel • Updated Oct.

Original title: “As biotech recovers, venture firms’ preferences appear to shift | BioPharma Dive”

M&amp;A has been steady in 2024. We count <strong>47 private &amp; public deals to date totaling $53 billion</strong>. 15 have been &gt;$1 billion with cancer, rare disease &amp; cell therapies some of the areas of interest.

Original title: “Biotech IPOs and M&As in 2020”

Looking ahead, CAMP4 intends to ... system (CNS) diseases. <strong>The funds from the IPO will be used to advance clinical trials, expand the RAP platform and support future product development initiatives</strong>....

Original title: “Biotech IPOs in 2024: Navigating the New Wave of Innovation - Xtalks”

CEO Neil McFarlane told BioSpace that Zevra has had varying funding approaches throughout the years, including royalty financing, equity, debt and M&amp;A. “We did both mergers and acquisitions to create Zevra, as well as invested in innovation that was our own technology to get products approved, and also acquired other assets,” McFarlane said.

Original title: “Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D - BioSpace”